Private Equity Owns a Third of America's Methadone Clinics. The Clinic Count Barely Moved.

Three mornings a week, Amber Titus wakes at five to make a 45-minute drive to a clinic that closes before lunch. She is 38, lives in Bisbee Junction, Arizona, near the Mexican border, and takes methadone for opioid use disorder. The nearest place licensed to give it to her is in Sierra Vista, about 30 miles away, and the window is narrow: arrive ten or fifteen minutes late and the dose is gone even though the doors are still open.

In August her car was totaled. Until she replaced it she relied on rides arranged through Medicaid, and the driver was late every day. "I missed my methadone dose for the whole week," she told The Conversation.

Titus's week is the human version of a market structure, and the structure is the subject of a piece published Oct. 28 by Yashaswini Singh, a health economist at Brown University's School of Public Health. Her finding is narrow and uncomfortable: private equity firms now hold roughly a third of the country's opioid treatment programs, and the number of places dispensing methadone has not grown to match.

The Arithmetic of a Market That Cannot Grow

As of October 2026, 1,572 methadone clinics are registered with the Centers for Medicare & Medicaid Services. Thirty-five percent of opioid treatment providers are affiliated with private equity firms. In 19 states and the District of Columbia, more than half have private equity owners.

Those facts sit oddly together. Capital flowed in; capacity did not follow. In Montana there are four clinics, all owned by Community Medical Services. In North Dakota the same company owns three of the state's four.

The clinics that exist were not built by their new owners. "Private equity firms haven't been building new capacity — they've been buying up the capacity that already existed," Singh writes. Wider access to methadone is the largest unused lever in the overdose crisis: the drug cuts fatal overdose risk roughly in half, and only about 22 percent of people with opioid use disorder ever receive it. More than 120 people a day died of opioid overdoses in 2025, according to federal estimates.

Opioid addiction treatment in the United States has been organized around a bottleneck since the 1970s: methadone could be dispensed only at federally certified opioid treatment programs, not by ordinary doctors or pharmacies. The rule was written to prevent diversion in an era when the drug was mostly a heroin substitute. It has survived five decades, one epidemic, and the arrival of fentanyl.

Why a Regulated Drug Becomes a Monopoly Asset

The regulation is what makes the asset attractive. Because the license is scarce, demand is guaranteed and geographically captive — whoever holds the clinics in a region holds the medication.

Average one-way drive times approach 50 minutes in rural communities. Many programs still require in-person dosing every day. Federal rules were loosened in 2024 to allow more take-home doses, but practice has lagged: only 19 percent of people who received take-home methadone got three or more days' supply. Daily attendance is less a legal requirement now than an operating choice — and it is the choice that keeps a waiting room full.

Singh describes the acquisition pattern as a platform-and-add-on strategy: buy one large clinic, then steadily absorb smaller ones nearby. "Individually, each deal looks too small to matter," she writes. "Collectively, a single firm can end up controlling an entire region's methadone supply."

She is explicit that private investment is not inherently harmful. Where quality is visible, competition real and the customer pays directly — restaurants, her example — private equity can be neutral or beneficial. Health care has none of those properties: patients cannot judge quality, they rarely pay the bill, and government is both payer and regulator.

What the Acquisitions Actually Changed

The Health Affairs analysis, co-authored with researchers at the University of Pittsburgh and RAND, identified 357 private-equity-acquired opioid treatment programs across 43 states between 2011 and 2022. Over that window the share of U.S. programs with any private equity investment rose from 0.26 percent to 18.9 percent, and most acquisitions ran through one of three large platforms.

The geography inverted the usual pattern. Private equity in most of health care clusters in dense, affluent metros; in opioid treatment the heaviest penetration was in Tennessee, Ohio and Kentucky — states the epidemic hit hardest.

What followed was mostly nothing. Methadone shipments to acquired programs rose 13 percent relative to programs that were not acquired, but the difference lost statistical significance once the researchers adjusted for the possibility that investors bought clinics already expanding. At the county level, methadone shipments and opioid mortality were unchanged.

Singh's earlier work, covering 2011 to 2019, found that within two years of a firm entering a county it typically controlled 67 percent of the local methadone market. In more than a quarter of counties, a single firm controlled all of it.

The Buprenorphine Trade-Off

Methadone's evidence base has a gap that buprenorphine fills, which is why a separate study belongs alongside it. A JAMA Network Open analysis published in March by Holdaway and colleagues at Wharton, Yale and Brown compared 90 acquired treatment facilities against 2,374 never-acquired ones between mid-2019 and mid-2021.

Volume rose. Acquisition was associated with a mean increase of about 66 additional patients receiving buprenorphine per facility per quarter, and about 164 additional prescriptions.

Retention fell. Ninety-day retention dropped 6.24 percentage points after acquisition, and 180-day retention dropped 7.91 points. Early discontinuation is one of the strongest predictors of relapse and overdose, and 180-day retention is the national quality benchmark.

Read together, the two studies describe a shape of consolidation: more people entering treatment, fewer staying in it, no new doors opening. That is not a sector expanding capacity; it is one optimizing throughput inside a fixed footprint. Comparable retention data for methadone do not exist, because opioid treatment programs are not measured that way.

The Clinics That Stayed Open

There is a version of this story in which private equity shuts rural clinics, and the record does not support it either.

In 2018 a prospective investor advised shuttering Community Medical Services' Montana and North Dakota locations as unprofitable. Nick Stavros, the chief executive, instead partnered with a different private equity firm to keep them running. Before outside investment CMS had 14 clinics in four states; it now reports 79 in 14 states, including five inside prisons and three mobile units, and Stavros says 49 of those came from new sites.

None are in Montana. A new clinic costs about $2.5 million, Stavros told The Conversation, more than many rural areas can support — arithmetic that binds a nonprofit exactly as it binds a fund.

That reframes the policy question. The failure here is not extraction from rural markets; it is non-expansion into them, and no ownership model solves a market where fixed cost exceeds the patient base. The only intervention that adds rural methadone access without adding a building is letting pharmacies dispense the drug.

A Bill, a Trade Group and an Uncomfortable Overlap

That is what the Modernizing Opioid Treatment Access Act would do. A version introduced in 2023 died without reaching a floor vote. It has returned as Modernizing Opioid Treatment Access Act 2.0 — H.R. 9790 in the House, S. 4941 in the Senate — and sits with the Energy and Commerce and Judiciary committees. No markup has been scheduled, and the term ends in January 2027.

Representative Donald Norcross of New Jersey, a sponsor, recalled a single line of footprints crossing an empty street to a methadone clinic during a snowstorm. "I realized that no matter what else is happening in the world," he said, "some of our neighbors' lives literally revolve around getting to that building every single day."

The bill has broad backing from patient advocacy groups and medical societies. A STAT investigation found the main opposition comes from the American Association for the Treatment of Opioid Dependence, the trade group representing the clinics themselves, which argues that wider prescribing and pharmacy dispensing would increase diversion and overdose.

The evidence for that claim is thin. Mark Parrino, the group's president, told The Conversation that AATOD objects on narrower grounds: the bill would let the HHS secretary decide which practitioners may prescribe methadone, and would permit a dispersible tablet alongside the liquid. Tablets "were definitely" involved in a rise in methadone deaths from about 1999, he said — a rise the CDC attributed to methadone prescribed for pain, not addiction.

Dr. Melody Glenn, an associate professor of addiction and emergency medicine at the University of Arizona who previously worked in a Tucson methadone clinic, supports the bill and thinks it should go further. "It's time to remove the regulatory barriers to these lifesaving medications," she said. "They don't have to die."

The overlap worth naming: the organization best positioned to slow pharmacy dispensing is funded by operators whose revenue depends on dispensing staying where it is. That is a conflict to weigh, not a conspiracy to allege — and the safety argument would carry more weight if the sector's own record on daily attendance were not itself a barrier to care.

The Enforcement Gap Nobody Designed

Two structural facts explain why consolidation this size stayed invisible.

The first is disclosure. Private equity is exempt from reporting rules that bind public companies, so neither regulators nor researchers can see ownership without the forensic work Singh's team did — algorithmic matching, geocoding, manual verification of deal records. Indiana, California and Maine have enacted or proposed ownership disclosure as a condition of billing Medicare or Medicaid; Vermont passed similar legislation this year, and Singh testified in support.

The second is antitrust review. The Federal Trade Commission and Justice Department treat control of 30 percent or more of a local market as a red flag. Singh's research shows firms typically reach 67 percent within two years of a first purchase in a county. Most of those deals never trigger federal reporting, because the requirement covers only transactions above roughly $134 million and the acquisitions arrive as small ones. Some states have floated a $10 million threshold for health care deals, which would surface most of them before closing.

Meanwhile the political pressure has started. Sen. Maggie Hassan of New Hampshire has opened an investigation into three of the largest methadone clinic operators, citing concerns that they oppose expanding access for financial reasons rather than safety ones.

What This Reporting Can and Cannot Show

Singh's account is an argument by a researcher with a stake in the conclusion. The Health Affairs study is observational: it can show that acquisitions did not coincide with expanded supply, but buying is not random, and clinics attractive to buyers may differ from independent ones in ways no adjustment captures. The buprenorphine study shares that limit and concerns a different medication and channel.

None of that touches the structural point, which requires no causal inference. A third of the national market is owned by financial firms. Two-thirds of some local markets are controlled by a single one. The clinic count is 1,572. And the medication that halves overdose risk reaches roughly one in five people who need it.

The Number to Watch

If Congress passes the pharmacy-dispensing bill, the test is not whether the clinic count rises — it will not — but whether the share of people receiving medication-assisted treatment moves off 22 percent. If it fails, the number to watch is ownership: 35 percent today, in a market where the reporting threshold means nobody must announce the next purchase.

Amber Titus, who now works for a harm reduction nonprofit in rural southeast Arizona, puts the access question in terms her own week made concrete. "Addiction isn't a choice," she said. "It's a learning curve and eventually … you get tired of it and you want help."

The help exists. Whether it is 45 minutes away, and open for four hours, is a business decision.